For better or for worse right. I mean, if APT didn't exist, doubt we'd even be at these prices. There's definitely opportunity cost priced into these stocks, hoping one will follow the success of APT.
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status
